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Summary 
Peptides from the lumenal portion of invariant chain (Ii) spanning residues 80--106 (class II- 
associated Ii peptide [CLIP]) are found in association with several mouse and human major his- 
tocompatibility complex (MHC) class II allelic variants in wild-type and presentation-deficient 
mutant cells. The ready detection of these complexes suggests  that such an intermediate is es- 
sential to the MHC class II processing pathway. In this study, we demonstrate that T  cells rec- 
ognize CLIP/MHC class II complexes on the surface of normal and mutant cells in a manner 
indistinguishable from that of nominal antigenic peptides. Surprisingly, T  cell hybrids specific 
for human CLIP bound to routine MHC class II molecule I-A  b and a new monoclonal anti- 
body 30-2 with the same  specificity, recognize two independent epitopes expressed on this 
peptide/class II complex. T  cell recognition is dependent on a Gln residue (position 100)  in 
CLIP, whereas the 30-2 antibody recognizes a Lys residue at position 90. These two residues 
flank the 91-99 sequence that is conserved among human, mouse, and rat Ii, potentially repre- 
senting an MHC class II-binding site. Our results suggest that the COOH-terminal portion of 
CLIP that includes TCR contact residue Gln 100 binds in the groove ofI-A  b molecule. More- 
over, both T  cells and the antibody recognize I-A  b complexed with larger Ii processing inter- 
mediates such as the "-'12-kD small leupeptin-induced protein (SLIP)  fragments. Thus, SLIP 
fragments contain a CLIP region bound to MHC class II molecule in a conformation identical 
to that of a free CLIP peptide. Finally, our data suggest that SLIP/MHC class II complexes are 
precursors of CLIP/MHC class II complexes. 
1  Tnvariant chain (Ii)  is a type II transmembrane glycopro- 
Jktein transiently associated with MHC class II molecules- 
during their intracellular assembly and  transport  (1).  The 
association of class II with Ii interferes with peptide binding 
to the peptide-binding groove of MHC class II molecules 
(2-4). Large multimeric complexes of three Ii polypeptides 
and three MHC class II ot~3 dimers form rapidly in the en- 
doplasmic reticulum (ELL) (5). These complexes are trans- 
ported across  Golgi stacks  to the trans-Golgi  network and 
are sorted to the endosomal compartment (1). Several stud- 
ies in mice with a targeted disruption of the Ii gene dem- 
onstrated that this sorting event is to a large extent medi- 
ated by Ii (6-8). Earlier in vitro studies revealed an endosomal 
1Abbreviations used in this paper: CLIP, class lI-associated invariant chain 
peptide; ER, endoplasmic reticulum; HEL, hen egg lysozyme; HPLC, 
high performance  liquid chromatography;  Ii, invariant chain; SLIP, small 
leupeptin-induced  protein; TfR, transferrin  receptor. 
targeting signal in the first 16 amino acid residues in the cy- 
toplasmic  tail  of Ii  (9).  After  arrival  in  endosomes,  Ii  is 
cleaved by endosomal proteases. Studies using protease in- 
hibitors indicated that an aspartyl proteinase(s)  and a cys- 
teine proteinase(s) are sequentially involved in  endosomal 
degradation of Ii in B cells (10,  11).  In cells treated with a 
cysteine proteinase inhibitor,  leupeptin,  two major inter- 
mediates  of  Ii  processing  were  demonstrated  (10,  11). 
These  intermediates  are  NH2-terminal  21-24-kD  frag- 
ments of Ii (leupeptin-induced protein [LIP]) and 11-14-kD 
fragments (small leupeptin-induced protein [SLIP]). 
Sequence analysis of peptides associated with several al- 
lelic variants of human and mouse MHC class II in normal 
cells demonstrated an abundant set ofpeptides with ragged 
NH2- and COOH-termini derived from Ii residues 80-106 
(12-15). Importantly, these peptides are associated with the 
majority of MHC  class II  molecules expressed in human 
presentation deficient mutant cell lines. The peptides were 
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ies using a  series of deletions in the lumenal portion of Ii 
indicate that the same 80-110 region of Ii is essential for its 
binding to MHC  class II (17-19).  Altogether, these results 
suggest that CLIP/MHC  class II complexes are essential in- 
termediates in the MHC  class II processing pathway.  The 
relationship between  CLIP and larger Ii fragments such as 
LIP  and  SLIP,  however,  remains  unclear.  Thus,  it is  not 
known whether CLIP represents a remnant ofli still associ- 
ated with MHC  class II after Ii truncation (12)  or, alterna- 
tively, if CLIP is first released during Ii proteolysis and sub- 
sequently rebinds in the peptide-binding groove (12, 16, 20). 
To address these questions, we have generated and char- 
acterized  a  panel  of  T  cell  hybrids  recognizing  human 
CLIP  peptides  bound  to  mouse  MHC  class  II  molecule 
I-A  b. Using these T  cells and a new mAb, 30-2, which rec- 
ognizes the same complex (Eastman, S., M. Deftos, P. De- 
Roos,  D.  H.  Hsu,  L.  Teyton,  N.  S.  Braunstein,  C.  J. 
Hackett,  and A. Yu.  Rudensky,  manuscript submitted for 
publication), we show here that the CLIP region of Ii binds 
to MHC  class II molecule in a conformation similar to that 
of the free peptide. Mapping of antibody and T  cell epitopes 
within  the  CLIP  peptide allowed us  to  identify the  con- 
served 91-99  region of Ii as a peptide capable of competi- 
tively inhibiting MHC  class  II  binding to  antigenic pep- 
tides.  Further,  we  demonstrate  that  the  ~12-kD  SLIP 
fragment of li is a  precursor of CLIP.  Our data suggest a 
model of CLIP binding to I-A  b with the COOH  terminus 
of this peptide bound in the MHC  class II-binding groove. 
Materials and Methods 
Mice.  C57BL/6,  BALB/c,  and  B6.C-H-2  bin12  mice  were 
purchased from The Jackson Laboratory (Bar Harbor, ME). 
Antibodies.  The  mAb  30-2  recognizing human  CLIP/I-A  b 
complex was  generated  in  our  laboratory (Eastman,  S.,  et  al., 
manuscript submitted for publication), and the the YAe antibody 
recognizing complex of I-A  b molecule with Ec~52-68 peptide was 
characterized earlier (21).  The  mAbs PIN.1  and  1G12,  which 
recognize the cytoplasmic tail of the human Ii chain (5) and hu- 
man  transferrin  receptor (TfR),  respectively, were  kindly pro- 
vided by Dr. Janice Blum  (University of Indiana, Indianapolis, 
IN). Antibody BU45 against lumenal portion of human  Ii chain 
was purchased from The Binding Site (San Diego, CA). Mouse 
hybridoma HP6035  producing mAb against human  Ig K chain 
was purchased from American Type Culture Collection (Rock- 
ville, MD).  Antibody Y237,  which recognizes I-A  b, was  kindly 
provided by Dr. Donal Murphy (New York State Department of 
Health, Albany, NY). Hybridomas secreting l-Ab-specific mAbs 
Y3P,  AF6-120.1.2,  and M5/114  are maintained in  our labora- 
tory. All antibodies were purified from culture supernatants or as- 
citic fluids on protein G-Sepharose columns. 
Cell Lines.  The mouse B cell lymphoma LB27.4 (I-A  bxa) was 
cotransfected with a genomic construct of the human Ii (gift from 
Dr.  Paul  Roche,  National Institutes of Health,  Bethesda,  MD) 
and a vector carrying the neomycin resistance pMClpA. Trans- 
fectants were selected for Ii expression by Western blotting of cell 
lysates using the anti-human Ii antibody PIN. 1. The T2 cell line 
and T2  transfected with I-A  k (22)  were provided by Dr.  Peter 
Cresswell  (Yale  University, New  Haven,  CT).  T2  cells  trans- 
fected with  I-A  b were characterized earlier (Eastman,  S.,  et al., 
manuscript submitted for publication). The human lymphoblas- 
toid B cell line Sweig was transfected with I-A  b o~ and 13 cDNAs 
cloned into expression vectors pNA and pHA carrying neomycin 
and hygromycin resistance genes, respectively, and was screened 
for surface  expression of I-A  b using Y3P and AF6-120.1.2 anti- 
bodies. T  cell hybridomas CLIP 51.5,  CLIP 51.10,  CLIP 51.11, 
CLIP  51.24,  CLIP  51.26,  CLIP 51.31,  CLIP  51.38,  and CLIP 
51.40 were generated by fusion ofBW5147 o~-[3- thymoma with 
activated lymph node T  cells from H-2  b mice immunized with 
human CLIP (Ii81-104) peptide in CFA. Alloreactive T  cell hy- 
bridoma BPB211  specific for  I-A  b was  generated by  fusion  of 
BW5147  cells with  activated lymph node  cells  derived from  a 
B10.Br (H-2  k) mouse immunized with cells expressing I-A  >. 
All  cell  lines  have  been  maintained  in  RPMI1640  supple- 
mented with 5%  FCS, L-glutamine, penicillin/streptomycin (all 
from GIBCO BRL, Gaithersburg, MD) in a 5% CO2 atmosphere 
at 37~ 
Peptides.  Peptides were synthesized using an automated pep- 
tide synthesizer (Synergy 432:  Applied Biosystems, Inc.,  Foster 
City, CA) using F-moc chemistry. Peptides were analyzed by re- 
verse-phase HPLC. Purity of the peptides used in this study was 
greater than 90%. 
T Cell Assays.  5  X  104  T  cell hybridomas were  cocultured 
with 5 X  104 APCs per well in 200 I*1 of supplemented RPMI in 
96-well flat-bottomed tissue  culture microplates at 37~  in the 
presence of titrated amounts  of peptides. After 18  h  of culture, 
50-1xl aliquots of culture supernatants were tested for IL-2 using 
the IL-2-sensitive indicator cell line HT2 (5 X 103 cells per weU). 
After 20 h of culture, 10 I~1 of  Alamar Blue solution (Alamar Bio- 
sciences, Sacramento, CA) was added to the wells, color reaction 
developed for 18 h at 37~  and OD (As70/60{}) was measured us- 
ing an  ELISA plate reader (EL311;  Bio-Tek Instruments,  Wi- 
nooski, VT). To assay T cell response to MHC class II molecules 
captured by anti-MHC antibodies, ELISA microplates (Im,nulon 
4; Dynatech, Chantilly, VA) were coated overnight at 4~  with 
30-2, anti-I-A  b, or control antibodies (5 Ixg/ml in PBS, pH 8.0, 
50 Ixl per well). Since PIN.1 mAb loses its activity during purifi- 
cation, in experiments with the lysates of leupeptin treated cells, 
plates were coated with goat anti-mouse IgG-Fc antibodies (Ac- 
curate Chemical and Scientific Corp., Westbury, NY)  followed 
by PIN.1  antibody, anti  I-A  6,  or control antibodies containing 
culture supernatants.  The plates were then blocked with PBS con- 
taining  1% BSA and 0.4%  NP-40  (Sigma),  washed  three  times 
with PBS, 0.1% NP-40. Cell lysates (50 txl per well) were added 
and  incubated  overnight  at  4~  The  wells were  subsequently 
washed with PBS, 0.1% NP-40 with PBS, 1% BSA, and finally with 
RPMI, 5% FCS, three times each. T cells were added to the plate, 
and overnight culture supernatants were tested using HT2 cells. 
Cell Lysates,  Western Blotting, and MHC Class II ELISA.  Cells 
were harvested in the logarithmic phase of growth, washed twice 
with PBS,  and lysed at  107  cells per ml  in  PBS  containing 1% 
NP-40, 5 mM EDTA, 0.1 mM PMSF, 0.2 mM TLCK, 10 U/nil 
aprotinin for 20 rain on ice. Lysates were cleared by centrifuga- 
tion at 16,000g at 4~  To enrich for SLIP fragnnents in some ex- 
periments, 2.5  X  107 T2-I-A  6 cells were cultured in the presence 
of 100  btg/ml leupeptin for 24 h,  lysed as described above, and 
treated with 200  Ixl of mAb BU45-coated protein A-Sepharose 
(Phannacia,  Uppsala,  Sweden)  (200  Ixl of ascites  per  1.2  ml  of 
50%  gel slurry)  for  1 h  in  4~  The  Sepharose beads were re- 
moved  by centrifugation,  supernatants  were  collected, and  the 
procedure was repeated five times followed by a 2-h incubation 
with protein A-Sepharose. SDS-PAGE and Western blot analysis 
1404  T Cell Recognition of Invariant Chain Processing Intermediates was performed as described before (21). Briefly, 50, 10, and 2 p~l 
of the lysates were run over 10-20% polyacrylamide gradient gels 
and transferred onto nitrocellulose filters. Ii and its fragments con- 
taining intact  cytoplasmic tail were  detected with  PIN.1  anti- 
body.  The  MHC  class  II  sandwich  ELISA was  previously de- 
scribed (Eastman,  S., et al., manuscript submitted for publication). 
Peptide-binding Assay.  Peptide binding to I-A  b on the live B 
cells  was  performed  as  described  before  (Eastman,  S.,  et  al., 
manuscript submitted for publication). Briefly, splenocytes from 
C57BL/6 mice were depleted of T  cells by treatment with anti- 
Thy-1 antibody Y19 and complement. Live B cells were isolated 
by centrifugation over a Ficoll density gradient. 3-4 ￿  l0  s B cells 
were preincubated with or without inhibitor peptides for 1 h at 
37~  5% CO2, in 50 I*1 of supplemented R.PMI in the wells of 
round-bottomed 96-well plates. After this first incubation, refer- 
ence peptide E(x52-68 was added to each well in 20 I*1 of supple- 
mented R.PMI at final concentrations of 6,  20, and 60 ~M, and 
was incubated for 4 h as described above. Cells were stained with 
YAe antibody and analyzed on a FACScan  |  flow cytometer (Bec- 
ton Dickinson & Co., Mountain View, CA). 
Biosynthetic Labeling and Immunoprecipitation.  Pulse-chase label- 
ing of cells with  [35S]methionine/cysteine (Tran3SS-Label;  ICN, 
Costa Mesa,  CA)  in  the  presence of 100  Ixg/rnl leupeptin and 
immunoprecipitation  were  performed  as  previously  described 
(Eastman,  S.,  et al., manuscript submitted for publication). Im- 
munoprecipitates were  analyzed by  Tris-tricine SDS-PAGE  as 
described previously (23). 
Results 
CLIP/I-Ab-specific  T  Cells and mAb Recognize  Different 
Epitopes,  To define interactions of class II with Ii peptide, 
a panel of T  cell hybridomas was generated by immuniza- 
tion of H-2  b mice with  human  CLIP  peptide and  subse- 
quent  fusion  of  activated  lymph  node  cells  with  the 
BW5147  fusion partner.  Six hybridomas were selected for 
their response to synthetic CLIP peptide--pulsed C57BL/6 
splenocytes and cloned by limiting dilution. All of the hy- 
bridomas  responded  to  CLIP  presented  by  C57BL/6  (I- 
Ab),  but  not  by either BALB/c  (I-A  d)  or bin12  (I-A  bm12) 
splenocytes (Fig. 1 a). Control I-A  b binding HEL74-88  or 
Eo~52-68  peptides as  well as  mouse  Ii81-104  peptide  did 
not induce any response in these T  cells (data not shown). 
Experiments using mouse B  cell lines transfected with hu- 
man  Ii and  human  B  cells transfected with  I-A  b demon- 
strated that CLIP-specific T  cells recognize naturally occur- 
ring CLIP/I-A  b complexes on the surface of wild-type and 
antigen  processing-deficient cells,  as  shown  in  Fig.  1  b. 
Nontransfected T2  cells did not activate T  cells, while T2 
cells expressing I-A  b molecule did. Similarly, human B  cell 
line Sweig was able to stimulate T  cell hybridomas only af- 
ter  transfection  with  I-A  b genes.  Finally, T  cell hybrido- 
mas  did not  respond to  mouse  B  cell lymphoma  LB27.4. 
However,  these  cells  transfected  with  human  Ii  gene 
(LB27.4huli) induced strong T  cell response (Fig, 1 b). 
To compare the specificity of T  cell hybrids with that of 
previously described CLIP/I-A  b mAb,  30-2  (Eastman,  S., 
et al., manuscript submitted for publication) we performed 
antibody-blocking  experiments.  Surprisingly,  T  cell  re- 
sponse to CLIP was not blocked by the 30-2 antibody. In 
contrast, some but not all I-Ab-specific antibodies inhibited 
T  cell response (Fig. 2, data not shown). In controls, differ- 
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Figure 1.  CLIP-specific T cells respond to synthetic and naturally processed CLIP peptide bound to I-A  b. (a) C57BL/6  (I-Ab), B6.C-H-2  bin12 (I- 
Abm12), and BALB/c (I-A  a) splenocytes pulsed with titrated amounts of synthetic CLIP (Ii81-104) peptide stimulate T cell hybridoma 51.24. (b) CLIP- 
specific 51.24, 51.26, and 51.31 T cell hybrids respond to naturally processed CLIP presented by human T2 and Sweig cell lines transfected with I-A  b or 
by the mouse I-Ab-positive LB27.4 B cell line transfected with human Ii. Corresponding nontransfected cell lines were used as controls. T cell activation 
was measured by the IL-2-dependent HT-2 cell line using Alamar blue colorimetric assay. 
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Figure 2.  Inhibition of CLiP-specific T cell response by some, but not 
all, anti-I-A  b mAbs. LB27.4 cells were incubated with Ii81-104 peptide 
(1 Ixg/ml) and antibodies (10 p,g/ml) and CLIP-specific  hybridoma 51.31 
(hatched bars). The alloreactive I-A  b specific-hybridoma  BPB211 was used 
as a control (filled bars). Background response of BPB211 hybridoma to 
syngeneic (H-2  k) spleen cells was <OD 0.10 (represented by 100 on the 
scale). T cell response was measured as described above. 
Table 1.  Sequences  of Synthetic Ii Peptides 
81  85  90  95  i00  i04 
Ii81-i04  LPKPPKPVSKMRMATPLLMQALPM 
**  *  **** 
Ii81-99  LPKPPKPVSKMRMATPLLM 
Ii81-93  LPKPPKPVSKMRM 
Ii81-91  LPKPPKPVSKM 
Ii85-i04  PKPVSKMRMATPLLMQALPM 
Ii91-i04  MRMATPLLMQALPM 
Ii93-i04  MATPLLMQALPM 
Ii89-i01  SKMRMATPLLMQA 
Ii85-99  KPVSKMRMATPLLM 
Ii91  99  MRMATPLLM 
Ii91-104(100R)  MRMATPLLMRALPM 
Ii91-104(101P)  MRMATPLLMQPLPM 
Ii91  I04(I02M)  MRMATPLLMQAMPM 
Ii91-I04(I03S)  MRMATPLLMQALSM 
Ii81-I04  LPKSAKPVSQMRMATPLLMRPMSM 
(mouse 
sequence) 
* Residues that are different in mouse and human CLIP sequences 
ential  inhibition  of response  of I-Ab-specific  alloreactive 
hybrid by this panel of antibodies was demonstrated. 
Fine Specificity of CLIP/LA b Recognizing  T  Cells.  To  map 
the  T  cell recognition site within  the  CLIP sequence,  we 
synthesized a series of truncation variants of the CLIP pep- 
tide (Table  1) and analyzed their ability to induce T  cell re- 
sponse and to bind to the I-A  b molecule. COOH-terminal 
truncation variants lacking residues  100-104 failed to stim- 
ulate T  cell hybridomas (Fig. 3 a, peptides Ii81-99, Ii81-93, 
and Ii81-91).  In contrast, Ii85-104 peptide with the NH 2- 
terminal truncation stimulated T  cells as strongly as the full- 
length  CLIP peptide  (Ii81-104).  This  suggests,  that  the  T 
cell  recognition site(s)  is  contained within  COOH-termi- 
nal portion of the CLIP peptide.  Since sequences of mouse 
and human Ii are identical between residues 91 and 99, we 
suggest that T  cell specificity is confined to four residues, 
100-103,  at which mouse  and human  Ii sequences  differ. 
We generated four peptide variants with single amino acid 
substitutions  changing human Ii residues for corresponding 
mouse  residues.  Two  of these  peptides  with  102  Leu 
Met  and  103  Pro---)Ser mutations  induced  response  of T 
cells  similar  to  that  of the  wild-type  Ii91-104  peptide 
(Fig.  3  b,  peptides  Ii91-104,  Ii91-104102M]  and  Ii91- 
1041103S]).  Proline substitution  for alanine at position  101 
(101  Ala  ---) Pro)  decreased  T  cell  response  significantly. 
The substitution ofglutamine at position 100 with arginine 
(100  Gln  ~  Arg),  however,  abolished  the  response  com- 
pletely  (Fig.  3  b,  peptides  Ii91-104,  Ii91-1041101P]  and 
Ii91-1041100R]),  indicating  that  Gln  100  is  critical  for T 
cell  recognition.  Furthermore,  truncated  peptide  Ii89-101 
was  able  to  activate  T  cells  similarly  to  peptide  Ii91-104 
(Fig.  3  a).  Interestingly,  this  peptide  is  recognized by the 
30-2  antibody as  well,  since  it  contains  Lys 90,  a  critical 
residue  for  30-2  binding  (Eastman,  S.,  et  al.,  manuscript 
submitted for publication,  and data not shown). All CLIP- 
specific T  cell hybrids demonstrated the same pattern of re- 
activity  to  CLIP peptide  variants,  but  different  sensitivity 
(data not shown). 
Binding  of CLIP  Peptide  Variants  to  I-A ~ Molecule.  Since 
truncated and mutated variants of CLIP may differ in their 
ability to bind I-A  b, we compared their ability to compete 
for  I-A  b with  titrated  amounts  of a  known  I-Ab-binding 
peptide,  E~52-68.  Ecx52-68 binding to GA  b was measured 
using E~52-68/I-A  b complex-specific mAb YAe (21). The 
long  Ii81-104  peptide  (CLIP)  proved  to  be  an  efficient 
I-A  b binder (Fig.  4).  NH2- and COOH-terminal truncation 
variants Ii85-104, li91-104,  Ii85-99, Ii89-101, and Ii81-99 
bind to I-A  b with  similar  efficiency comparable to that  of 
CLIP.  Similarly,  single  amino  acid  substitutions  Gin100  -+ 
Arg, Alal01  -+ Pro, Leul02 -+ Met, and Pro103 -+ Ser in 
Ii91-104  peptide  did  not  affect  its  I-Ab-binding capacity 
(Fig.  4).  Since Ii91-104 and Ii81-99 peptides bind to I-A  b, 
we suggest that the  91-99 region they share  is responsible 
for their binding to MHC  class II. Indeed, further trunca- 
tions  reaching  into  the  91-99  region  from  both  ends 
sharply reduced their ability to compete for I-A  b. Peptides 
Ii81-93  and  Ii81-91  were  very inefficient  competitors  in 
this  assay  (Fig.  4).  To  directly  demonstrate  interaction  of 
this region of Ii with the I-A  b molecule, we synthesized the 
Ii91-99 peptide  and tested it in an E0~52-68 peptide  com- 
petition  assay.  As shown  in  Fig.  4,  this  peptide  competes 
for LA  b. This result indicates that Ii91-99 peptide is able to 
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Figure 3.  T  cell recognition of CLIP peptide variants. (a) The CLIP-specific T  cell hybrid 51.31  recognizes NH2-truncated forms of synthetic CLIP 
peptide (Ii89-104,  Ii89-101,  Ii91-104,  and Ii93-104),  but not COOH-truncated forms of CLIP (Ii81-99,  Ii81-93,  Ii81-91,  Ii85-99,  and Ii91-99).  (b) T 
cell responses to single amino acid substitution variants of Ii91-104 peptide. T  cell response was measured as above. 
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Figure  4.  Binding of CLIP and its variants to  I-A  b.  Competition of 
synthetic CLIP peptide variants with E~/2-68  peptide for I-A  b binding. 
Ea52-68 peptide binding to I-A  b was measured by YAe antibody staining 
of splenic B cells from C57BL/6 mice pulsed with 20 ~M E(x52-68 pep- 
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bind  to MHC  class  II molecule and  to prevent antigenic 
peptide binding in the peptide-binding groove. 
30-2 Antibody and T  Cell Epitopes Are Expressed on the Same 
I-A  b Molecule.  Mapping of T  cell recognition site within 
CLIP to Gin 100 and similar mapping of the 30-2 antibody 
site to Lys 90 (Eastman, S.,  et al., manuscript submitted for 
publication) does not exclude the possibility that T  cell and 
30-2 epitopes are expressed on different rather than on the 
same I-A  b molecule. For example, it is possible that the T 
cell  epitope  is  expressed after an  I-A  b molecule  re-binds 
free CLIP in the peptide-binding groove, whereas the 30-2 
epitope  may be  expressed by an  I-A  b molecule  with  the 
CLIP region of Ii still attached after removal of the rest of 
the  Ii.  To address this  question,  we assayed the  ability of 
MHC class II molecule/CLIP complexes captured with the 
30-2 mAb to stimulate CLIP-specific T  cell responses. I-A  b 
complexes  from  T2-I-A  b  cell  lysates  were  captured  on 
plates coated with 30-2 antibody or the I-Ab~specific anti- 
bodies AF6-120.1.2,  M5/114,  and  Y3P,  and  were  incu- 
bated  with  CLIP-specific T  cells  (Fig.  5).  Class  II/CLIP 
complexes captured  on  30-2-coated  plates,  as well  as  on 
tide in the presence of 60,  200,  and 600 p,M inhibitor peptides. I-A  t'- 
binding HEL74-88 peptide  ^u2z was used as a positive control for inhibi- 
tion.  The  data  are  presented as  percent inhibition  of peptide binding 
calculated as (mean fluorescence intensity [MFI] in the presence of inhib- 
itor-background): (Mean Fluorescence Intensity [MFI] in the absence of 
inhibitor-background)  100.  Inhibition values <20%  are  considered not 
significant since this level of inhibition can be achieved at a high concen- 
tration ofnonspecific moth cytochrome C peptide (MCC8t-104). E~, 3￿ 
inhibitor; I,  10￿  inhibitor; F13, 30￿  inhibitor. A  600 
600 " 
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Figure  5.  T  ceils recognize  plate-captured  CLIP/I-A  b  complexes. 
51.24 T  hybrid  response to total I-A  b and CL1P/I-A ~ complexes from 
T2-I-A  b celt lysates bound to plates coated with 30-2 (filled circles), anti-I- 
A  b mAbs M5/114 (filled squares), Y3P (open squares),  and AF6 (open trian- 
gles). As a control, anti-human Ig K chain (small squares) and anti-human 
TflL  (small  triangles) antibodies were  used. Additionally, AF6, M5/114, 
Y3P,  and 30-2-coated plates were  preincubated  with T2-I-A  k lysates. 
The response to  all dilutions of T2-I-A  ~ lysate was  <OD 0.10 (repre- 
sented by 100 on the scale). T cell response was measured as above. 
AF6-120.1.2- or M5/114-coated  plates elicited a strong T 
cell response.  This suggests that  30-2-reactive I-A  ~ mole- 
cules are recognized by CLIP-specific T  cell hybrid. Quan- 
6tative  differences  in  T  cell  response  to  CLIP/I-A  b  com- 
plexes  captured  by  these  noninhibitory  antibodies  most 
likely  reflect  differences  in  their  affinities.  T2  cells  and 
T2-I-A  b transfectants express TfR and surface Ig, and they 
can be stained with mAbs against these molecules (data not 
shown). Anti-Ig K and anti-Tflk mAbs were therefore used 
to control for the nonspecific binding of I-A  b molecules to 
antibody-coated plates. As shown in Fig. 5, there was no T 
cell stimulation detected on plates coated with either con- 
trol antibody.  Similarly, I-A  k molecules from T2-I-A  k ly- 
sates  captured  on plates  coated  with  AF6-120.1.2  (recog- 
nizing I-A  k as well as I-A  b) did not induce any measurable 
IL-2 production.  Identical results were  obtained with sev- 
eral  other  CLIP-specific  hybrid  T  cell  lines  (data  not 
shown).  The low level of the response  to  complexes cap- 
tured on the Y3P antibody at the highest concentration of 
cell lysates is probably caused by some minute aggregation 
of I-A  b in the lysates. 
Potential aggregation of MHC  class  II molecules giving 
rise  to  mixed 30-2 +  and 30-2-  I-A  b aggregates  could ac- 
count for  the  observed  T  cell responses  to  30-2-captured 
I-A  b molecules. To rule this out, we performed a sandwich 
ELISA using the same I-Ab-specific antibody as a first anti- 
body immobilized on the solid phase and as a second anti- 
body in the fluid phase to detect homoaggregates.  This im- 
munochemical approach did not reveal any aggregation of 
I-A  b molecules,  since  homologous  combination of plate- 
immobilized and biotinylated 30-2,  AF6-120.1.2,  and an- 
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Figure 6.  Analysis ofhomoaggregation of CLIP/GA  b complexes and 
I-A  b molecules captured on antibody-coated plates by a sandwich ELISA. 
Determination ofI-A  b from T2-I-A  b cell lysates on Y3P-coated plates us- 
ing biotinyiated Y3P (a) and AF6 (d) antibodies. Detenrfination of CLlP/ 
I-A  b complexes from T2-I-A  b cell lysates on 30-2-coated plates using bi- 
otinylated 30-2  (b) and AF6 (e) antibodies. Determination of [-A  b and 
CLIP/GA  b complexes from T2-I-A  b cell lysates on AF6-coated plates us- 
ing biotinylated AF6 (c), Y3P ~, and 30-2 (g) antibodies. Ordinate  axis 
represents the dilution of cell lysates. Filled triangles, T2-I-A  b cell lysates; 
squares, T2 cell lysates (control). 
other  I-Ab-specific antibody, Y3P,  did not detect any sig- 
nal in T2-I-A  b lysates above  control  T2  lysates  incubated 
with the corresponding plates (Fig. 6  a-c).  In contrast, het- 
erologous combinations of antibodies readily detected I-A  b 
and CLIP/I-A  b complexes (Fig. 6  d-g).  In addition, we did 
not observe CLIP-specific T  cell responses on YAe-coated 
plates  incubated  with  I-Ab-transfected  Sweig  cell  lysates 
expressing both EoffD1Ko~)52-68/I-A  b and CLIP/I-A  b com- 
plexes (data not shown). Therefore, we conclude that non- 
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same population of I-A  b molecules associated with CLIP. 
I-A b Complexes  with  ~12-kD  Ii Fragments  Express  30-2 
and  T  Cell Epitopes.  Since  the  T  and  B  cell  epitopes  of 
CLIP/I-A b are independent,  30-2  antibody  and  T  cell hy- 
brids were used for analysis of conformation  of CLIP/I-A b 
and  for  identification  of CLIP  precursor(s)  among  larger 
fragments,  i.e.,  LIP  and  SLIP,  which  are  produced  during 
endosomal  degradation  of Ii.  Previously,  we  have  shown 
that 30-2 antibody does not recognize I-A  b molecules asso- 
ciated with intact Ii (Eastman,  S., et al., manuscript  submit- 
ted  for  publication).  To  reveal  expression  of  the  30-2 
epitope by complexes of LIP and  SLIP with I-A  b, we per- 
formed  immunoprecipitation  experiments  in  35S-methio- 
nine/cysteine pulse-labeled T2-I-A b cells treated with leu- 
peptin.  SDS-PAGE  analysis  in  Tris-tricine  gels,  which 
allow for better resolution ofpolypeptides with low molec- 
ular  masses,  revealed  identical  ~12-kD  bands  in  30-2, 
Y3P,  and  PIN.1  immunoprecipitates  from  drug-treated 
Figure  7.  CLlP/I-Ab-specific  antibody  30-2  recognizes  complexes  of 
I-A  b with Ii fragments  SLIP  Av27. SDS-PAGE analysis [35S]methionine/ 
cysteine pulse-labeled  T2-I-A  b cells treated  with leupeptin (100 p~g/ml) 
and immunoprecipitated  with 30-2, Y3P, and PIN. 1 antibodies after 0, 3, 
and  6  h  of chase. Immunoprecipitates  with Y17  and  anti-human  Ig K 
were used as controls. Samples were boiled and run over 17.5% Tris-tri- 
cine gels. Asterisk shows the position of~x and [3 chains in the gel. 
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Figure 8.  CLIP-specific  T  cells recognize  complexes  ofl-A  b with ~12-kD fragments ofli SLIP. 51.24 T  hybrid  response to SLIP/I-A  b complexes 
from (a) lysates of leupeptin-treated  T2-I-A  b cells, depleted  with BU45 mAb and captured  on PIN.l-coated plates (filled triangles), 30-2-coated plates 
(filled circles),  and M5/114-coated plates (filled  squares). (b) T cell response to complexes from lysates of untreated  T2-I-A  b cells captured  on PIN. 1- (open 
triangles), 30-2- (open circles),  and M5/114- (open squares) coated plates. Anti-human Ig K chain (small  circles)  and anti-human TfR (small  squares) antibodies 
were used as controls. Additionally, M5/114-, PIN.l-, and 30-2-coated plates were preincubated  with T2-I-A  k lysates. The response to all dilutions of 
T2-I-A  k tysate was ~<OD 0.10 (represented by 100 on the scale). T cell response was measured as above. 
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Figure 9.  Analysis  of homoaggregation ofSLIP/I-A  b complexes and I-A  b molecules in lysates ofleupeptin-treated  T2-1-A  b cells by sandwich EL1SA. 
Determination ofSLIP/[-A  b complexes in leupeptin-treated T2-I-A  B  cell tysates depleted with BU45 mAb on 30-2-coated plates using biotinylated 30-2 
(a), AF6 (b),  and Y3P (c) antibodies. Determination of GA  b in the same ceil [ysates on Y3P-coated plates using biotinylated Y3P (at), AF6 (e) and 30-2 
antibodies. Filled triangles, T2-I-A  b cell lysates; open squares, T2-I-A  b cell lysates; open squares, T2-I-A  k cell lysates (control). 
cells after 0, 3, and 6 h  of chase (Fig. 7). Since PIN.1  anti- 
body precipitates intact Ii as well as LIP and SLIP fragments 
containing  an  intact  cytoplasmic tail,  the  observed  12-kD 
fragments in  30-2  and Y3P  as well  as in PIN.1  immuno- 
precipitates  can  be  identified  as  SLIP.  Anti-human  lg  K 
chain  antibody  and  irrelevant  antibody  Y17  used  as  con- 
trols  did  not  precipitate  ~12-kD  polypeptides.  Similarly, 
these  bands  were  not  observed  in  anti-TflK  precipitates 
(data not shown).  Therefore,  SLIP/I-A  b complexes express 
the 30-2 epitope. 
To  demonstrate  expression  of  the  T  cell  epitope  on 
SLIP/I-A  b complexes,  we  tested T  cell responses  to these 
complexes captured on PIN. 1-coated plates. As a source of 
SLIP/I-A  b complexes we  used  lysates of T2-1A  b cells en- 
riched  for  these  complexes  by  overnight  culture  in  the 
presence  of 100  Ixg/ml  of leupeptin.  To  avoid  potential 
competition  of intact Ii with  SLIP fragments for the bind- 
ing  to  PIN.l-coated  plates,  lysates  were  extensively  de- 
pleted of intact Ii by treatment with BU45 antibody, which 
recognizes  the  lumenal  portion  of li  and  does  not  react 
with  SLIP  fragments  and  protein  A-Sepharose.  Western 
blot  analysis  of lysates  using  PIN.1  antibody  showed  (a) 
high level of expression of Ii fragments in  the presence  of 
leupeptin  and  (b) very efficient "~  depletion  of in- 
tact  Ii by BU45  adsorption  (data  not  shown).  SLIP/I-A  b 
complexes from BU45-treated  lysates captured on PIN.l- 
coated plates induced a strong response of CLiP-specific T 
cells comparable to that on M5/114  or 30-2-coated  plates 
(Fig. 8). To rule out potential oligomerization of SLIP/GA  b 
or mixed SLIP/CLIP/I-A  b complexes in the lysate ofleu- 
peptin-treated cells, we performed a sandwich ELISA anal- 
ogous to that shown above on Fig. 6. Similarly, we did not 
get a significant signal in the ELISA using homologous (30- 
2/30-2-biotin,  YBP/Y3P-biotin,  Fig.  9,  a and d) or heter- 
ologous  pairs  of plate-immobilized  and  biotinylated  anti- 
bodies  with  overlapping  epitopes  (30-2/Y3P-biotin  and 
Y3P/30-2-biotin,  Fig.  9, c andJ~.  In contrast,  a strong sig- 
nal was detected with heterologous pairs of antibodies with 
nonoverlapping epitopes (30-2/AF6-biotin  and Y3P/AF6- 
biotin,  Fig.  9,  b  and  e).  These  results,  as  well  as  low  re- 
sponse to I-Ab/Ii complexes from nontreated cells captured 
on PIN.I  (Fig.  8  b) antibody,  argue against aggregation  of 
SLIP/I-A  b  complexes.  It  is  not  unexpected,  since  Lip/ 
MHC  class  II nonamers  dissociate  in  nonionic  detergents 
1410  T CeII Recognition oflnvariant Chain Processing Intermediates (23a).  Thus,  we conclude  that both T  cell and 30-2  epi- 
topes are expressed by SLIP/I-A  b complexes, which strong- 
ly suggests  that  these  complexes are precursors  of CLIP/ 
I-A  b complexes. 
Discussion 
In this study, we demonstrated for the first time that T 
ceils  recognize complexes of MHC  class II molecules and 
Ii-derived  CLIP  peptides  in  a  manner  indistinguishable 
from that of conventional antigenic peptides. T  cell hybrids 
recognizing human CLIP bound to I-A  b generate a strong 
response to normal B  cell lines of human or mouse origin 
that coexpress human Ii and I-A  b (Fig.  1). In addition, the 
human  presentation-deficient  mutant  cell line  T2  and  its 
parental  cell  line,  T1,  transfected  with  I-A  b present  this 
complex very efficiendy to  CLiP-specific  T  cells.  These 
findings are in agreement with our studies of the expression 
of CLIP/I-A  b complexes in mutant and wild-type cells us- 
ing the mAb 30-2. This antibody specific for human CLIP/ 
I-A  b complexes cross-reacts with  corresponding  synthetic 
and endogenous mouse peptides bound to I-A  b (Eastman, 
S.,  et al.,  manuscript submitted for publication).  Immuno- 
histochemical  and  biochemical  studies  in  C57BL/6  mice 
and  bone  marrow  chimeras  using  the  30-2  antibody  re- 
vealed expression of these complexes on the surface of nor- 
mal  antigen-presenting  cells  in  spleen,  lymph nodes,  and 
thymus  (Farr,  A.,  and  A.  Yu.  Rudensky,  manuscript  in 
preparation).  Polyclonal T  cells  from C57BL/6  mice im- 
munized with  the  human  CLIP  develop  a  relatively low 
but significant in vitro proliferative response to this peptide 
(stimulation indexes 2--6).  In contrast,  T  cell responses to 
the mouse CLIP (Ii81-104 peptide), as well as to its  short 
variant Ii85-99  (12),  were not detected  (data not shown). 
Since mouse Ii peptides bind to I-A  b with a comparable or 
even higher affinity than corresponding human Ii peptides 
(Eastman, S.,  et al.,  manuscript submitted for publication), 
this indicates that T  cells are tolerant to mouse Ii peptides. 
The lack of T  cell response to mouse Ii peptides allowed 
us to study the fine specificity of CLIP-specific T  cell hy- 
brids by replacing nonconserved amino acid residues in hu- 
man  CLIP  sequence  with  corresponding  mouse  residues. 
This analysis demonstrated that all T  cell hybrids recognize 
the same residue of the CLIP peptide that is distinct from 
that recognized by the 30-2 antibody. Previously, we have 
identified the a lysine residue at position 90 of the human Ii 
as a critical residue for 30-2 antibody recognition (Eastman, 
S.,  et  al.,  manuscript  submitted  for publication).  In  con- 
trast, T  cell specificity is confined to the COOH-terminal 
portion of CLIP, particularly to glutamine at position 100. 
Interestingly, antibody and T  cell epitopes are not overlap- 
ping,  since  the  30-2  antibody  does  not  block T  cell  re- 
sponse to CLIP presented by I-Ab-positive APCs. In addi- 
tion,  CLIP/I-A  b complexes bound  to  30-2-coated  plates 
are efficiently recognized by T  cells,  which further proves 
that both T  cell and antibody epitopes are expressed on the 
same MHC class II molecule. Importantly, T  cell and anti- 
body recognition are both critically dependent, not only on 
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the  peptide,  but  also  on  the  MHC  class  II allele.  Com- 
plexes of CLIP with I-A  a and I-A  bm12 are not recognized 
by the  30-2  antibody  or the  T  cells  (Eastman,  S.,  et al., 
manuscript submitted for publication, and Fig.  1). The lat- 
ter differs from I-A  b at three amino acid residues at posi- 
tions 67, 70, and 71  (24). How can we explain the lack of a 
steric inhibitory effect of the 30-2 antibody on CLIP-spe- 
cific T  cell response, as well as the effect ofbml2 mutation 
on  both  TCIL and  antibody recognition?  First,  the  30-2 
antibody  may bind  from the  side  of the  MHC  class  II- 
binding groove with both CLIP residues Lys 90 and some 
I-A  b residues contributing to the binding site, whereas the 
TCk  may interact with the I-Ab/CLIP complex from the 
top of the groove.  It is possible that distinct  I-A  b residues 
affected by bm12 mutation contribute differently to T  cell 
and antibody epitopes. Another possible interpretation for 
these findings, which does not exclude the first one, is an 
indirect  effect of certain amino acid residues in the  CLIP 
(e.g.,  Lys 90)  or in  the  I-A  b (bm12  substitutions)  on the 
conformation of the  entire  complex.  Structural  analysis  is 
required to give a final answer to this question. 
Our analysis of the CLIP binding to I-A  b using the orig- 
inal  peptide  and  its  truncation  variants demonstrated  that 
the nonamer corresponding to the 91-99  region of Ii can 
bind to I-A  b and compete for the presentation with the an- 
tigenic Eot52-68 peptide. This part of the CLIP sequence is 
identical in  the mouse,  human,  and rat Ii (25-28),  and it 
suggests  that  the  conserved 91-99  region  of the  Ii is  the 
MHC class II-binding site.  These results are in agreement 
with several studies of Ii/MHC class II association using a 
series  of COOH-terminal  deletion  variants  of Ii  coex- 
pressed  with  human  and  mouse  MHC  class  II  (17-19). 
Freisenwinkel and coauthors demonstrated that the 80-110 
region  of the  Ii  is  necessary  for  the  Ii  association  with 
MHC  class  II  (17).  These  authors  postulated  binding  of 
CLIP  at  a  position  distinct  from  the  peptide-binding 
groove.  In  contrast,  R,  omagnoli  and  Gerrnain  (18)  sug- 
gested  a  model of CLIP binding  inside  the  groove while 
CLIP is still  a  part  of the  Ii1-107  fragment.  The latter is 
supported  by our findings.  A  recent  study by Bijlmakers 
and colleagues further narrowed the site of Ii/MHC class II 
interaction  to  residues  96-104  (19).  In  agreement  with 
these data, we did not find significant binding of the Ii81- 
93 peptide, in contrast to 93-104 peptide, which was able 
to bind to I-A  b and to elicit a T  cell response. These data 
suggest that the 91-99  peptide  of the  Ii may represent an 
MHC class II-binding site.  Interestingly, the Ii89-101 pep- 
tide, which contains the MHC class II-binding 91-99 site 
flanked with Lys 90, Gln 100, and Ala 101, which are crit- 
ical for 30-2 and T  cell recognition,  respectively, binds to 
I-A  b and is recognized by the antibody and T  cell (Figs. 3 a 
and 4). Recent study by Malcherek et al. (29) provided ev- 
idence  that  CLIP  may act  as  a  universal  groove-binding 
peptide, taking advantage of sequence supermotifs and al- 
lowing CLIP to bind to various MHC alleles.  All previous 
studies, as well as this one, do not exclude contribution of 
other regions of the  Ii, such as the transmembrane region 
or the more COOH-terminal parts of the lumenal portion of Ii, to its binding to MHC  class  II molecule.  These addi- 
tional sites may be critical for Ii binding to MHC  class II al- 
leles  with  a  relatively  low  affinity  for  CLIP,  e.g.,  HLA- 
DR4 or DR11  (15, 20). 
Our results suggest that the COOH-terminal  portion of 
the CLIP region, which includes T  cell contact residue Glu 
100,  binds  in  the  groove  of the  I-A  b molecule.  It  seems 
likely that the  orientation  of NH2  and  COOH  termini  of 
CLIP  associated  with  MHC  class  II follows  that  of anti- 
genic MHC-binding  peptides.  In this case,  the very NH2- 
terminal  portion  of CLIP  more  distant  from  the  MHC- 
binding  site  is likely  to  be  exposed  and  recognized  in  an 
MHC-independent  manner,  whereas  Lys 90  is still in  the 
groove or in its immediate proximity such that it is recog- 
nized by the 30-2  antibody in an MHC-restricted  fashion. 
This  model is supported  by the  observation  that  the  Cer- 
CLIP.1  antibody,  recognizing free as well as MHC-bound 
CLIP independently  of an MHC  allele (30), does not react 
with any of NH2-terminal truncation variants of CLIP used 
in  this  study  (Cresswell,  P.,  personal  communication).  In 
addition,  the  binding  of CLIP  to  I-A  b molecules  protects 
CLIP containing both T  cell and antibody recognition sites 
from cleavage by trypsin,  similarly  to  a  single  amino  acid 
substitution  variant  of  antigenic  EoL52-68  peptide  (57 
Glu--)Lys)  containing  a  single  trypsin  cleavage  site  in  the 
middle  of the  sequence  (Goldrath,  A.  W.,  and  A.  Yu. 
Rudensky,  unpublished  observation).  Similarly, CLIP pep- 
tide bound to the HLA-DR3 molecule was protected from 
proteolytic  degradation  by a  mixture  of cathepsin  B  and 
D  (20). 
The  T  cell  recognition  of CLIP/MHC  class  II  com- 
plexes raises a question  concerning the mechanism respon- 
sible for generating  of these  complexes.  In other words,  is 
CLIP  a  remnant  of the  Ii  containing  the  MHC  class  II- 
binding site that remains associated with MHC  class II after 
the  rest of the  Ii is cleaved off, or is this fragment first re- 
leased by proteases as a free peptide which then binds in the 
groove of MHC  class  II molecule? Generation  of CLIP/l- 
Ab-specific T  cells and mAb 30-2  provided us with  a tool 
to  compare  the  conformation  of I-A  b molecule  associated 
with  free  CLIP  peptide  and  I-A  b  complexes  with  larger 
fragments  of Ii  containing  the  CLIP  region.  These  frag- 
ments,  21-kD  LIP  and  11-14-kD  SLIP,  were  first  de- 
scribed in B  cell lines  treated  with  the  cysteine proteinase 
inhibitor  leupeptin  (10,  11).  LIP and  SLIP fragments  stay 
associated with  MHC  class  II molecules  in  the  endosomal 
compartment,  thus  preventing  class  II  export  to  the  cell 
surface (31). Both 30-2 antibody and CLIP-specific T  cells 
recognize complexes of I-A  b with N12 kD SLIP fragments 
(Figs. 7  and 8). Thus,  SLIP fragments contain CLIP region 
bound  to MHC  class  II molecule in a conformation  indis- 
tinguishable  from that of free CLIP peptide.  This indicates 
that  (a)  CLIP  is  a  remnant  of Ii and  (b)  SLIP/I-A  b com- 
plexes are precursors  of CLIP/I-A  b complexes.  SLIP frag- 
ments are generated  in late  endosomes and in a  dense  en- 
dosomal  compartment,  MIIC  (reference  11  and J.  Blum 
and  Rudensky,  A.,  manuscript  in  preparation).  Recent 
studies suggested that the latter compartment is a critical in- 
tracellular  site  for  MHC  class  II  complex  assembly  with 
peptides derived from both endogenous and exogenous an- 
tigens  (32-35).  Therefore,  it  is  likely  that  the  bulk  of 
CLIP/MHC  class  II  complexes  is  generated  in  the  same 
compartment.  Further  experiments  with  CLIP-specific  T 
cell  hybrids  and  the  30-2  antibody  using  subcellular  frac- 
tionation will directly test this prediction. 
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